Article Text

Download PDFPDF
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes
  1. Emma Magavern12,
  2. Teck K Khong3
  1. 1 William Harvey Research Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, UK
  2. 2 Department of Clinical Pharmacology, Cardiovascular Medicine, Barts Health NHS Trust, London, UK
  3. 3 Clinical Pharmacology, St George's, University of London, London, UK
  1. Correspondence to Dr Teck K Khong, Clinical Pharmacology, St George's University of London, London, UK; tkhong{at}


Commentary on: Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57.

Commentary by: Dr Emma Magavern and Dr Teck Khong Clinical Pharmacology, St George's, University of London, UK

Series Editor: Dr Teck Khong, DTB Associate Editor Clinical Pharmacology, St George's, University of London, UK

  • cardiovascular diseases
  • diabetes mellitus

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

  • Provenance and peer review Commissioned; internally peer reviewed.